What is TearSolutions?
TearSolutions specializes in developing advanced treatments for ocular surface diseases, with a particular emphasis on their proprietary peptide therapy, Lacripep. This groundbreaking, first-in-class treatment is designed to restore ocular surface health by addressing deficiencies in tear proteins, a critical need for patients suffering from conditions such as primary Sjögren's Syndrome. The company targets the prevalent issue of dry eye disease, which disproportionately affects older adults and is often exacerbated by environmental factors. With a robust leadership team and ongoing clinical trials, TearSolutions is strategically positioned to advance the field of ophthalmology.
How much funding has TearSolutions raised?
TearSolutions has raised a total of $23.9M across 5 funding rounds:
Series A
$3M
Private Equity
$3.4M
Private Equity
$8.1M
Debt
$6.4M
Series B
$3M
Series A (2015): $3M with participation from CIT, LaunchCapital, and Santen Pharmaceuticals Co., Ltd.
Private Equity (2017): $3.4M, investors not publicly disclosed
Private Equity (2017): $8.1M, investors not publicly disclosed
Debt (2019): $6.4M featuring Medarva Foundation, UVa Seed Fund, PharmStandard Ventures, and VTC Innovation Fund
Series B (2024): $3M, investors not publicly disclosed
Key Investors in TearSolutions
Santen Pharmaceuticals Co., Ltd.
Santen Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company with a strong specialization in ophthalmology, holding a leading position in the Japanese market and significant global presence in over 50 countries. Their focus on ophthalmic products aligns with TearSolutions' therapeutic area.
LaunchCapital
LaunchCapital is a venture capital firm dedicated to supporting entrepreneurs at the seed and early stages of development. Their investment in TearSolutions suggests a belief in the company's early-stage potential and innovative approach to ocular therapies.
CIT
The Center for Innovative Technology (CIT) focuses on technology-based economic development, providing crucial early-stage commercialization and seed funding. Their participation indicates support for innovative technologies emerging from research and development.
What's next for TearSolutions?
The substantial enterprise-level funding and recent strategic investment indicate a pivotal moment for TearSolutions. This capital infusion is expected to accelerate the company's development pipeline, potentially enabling broader clinical trial participation and the scaling of manufacturing capabilities for Lacripep. Further investment will likely support market penetration efforts and the expansion of their therapeutic offerings within the ophthalmology sector. The company's trajectory suggests a move towards commercialization and establishing a significant market presence in the treatment of dry eye disease and related ocular conditions.
See full TearSolutions company page
